Healthcare Services (HS1) AI Stock Analysis

Healthcare Services

(Frankfurt:HS1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Improved growth and marginsThe sharp increase in revenue, net income, and margins indicates stronger operating execution and improved earnings capacity. If management sustains recent client wins and cost discipline, the higher profitability base can support reinvestment and strengthen performance over the next several quarters.

Negative Factors

Volatile cash conversionAlthough current cash generation is positive and broadly aligned with earnings, the decline in free cash flow and history of uneven conversion reduce confidence in consistency. Variable cash generation can complicate acquisition funding, shareholder returns, and investment planning across future quarters.

Healthcare Services (HS1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.65B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 16.2
Beta (1Y): 0.64
Revenue Growth: -1.18%
EPS Growth: 164.21%
Country: Germany
Employees: 36,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

Healthcare Services Business Overview & Revenue Model

Company Description

Healthcare Services Group, Inc., established in 1976 and based in Bensalem, Pennsylvania, provides outsourced management and operational services to healthcare and senior living facilities nationwide. The company supports departments such as housekee...

Healthcare Services Earnings Call Summary

Earnings Call Date:Oct 20, 2026(Q3-2026)|% Change Since:16.76%|Next Earnings Date:Feb 16, 2027

Earnings Call SentimentPositive

The call was strongly positive, with robust third-quarter execution, revenue of $479.6 million, improving bad debt performance, a substantial liquidity position, the NEXDINE acquisition, and a raised 2027 growth outlook. Management also highlighted demographic tailwinds, strong client retention, and continued organic momentum. The principal challenges were uncertainty around additional Genesis recoveries, the volatility of bad debt and workers' compensation, M&A-related SG&A and lost interest income, and timing-related cash flow fluctuations.

Positive Updates

Ninth Consecutive Sequential Revenue Increase

Third-quarter revenue was $479.6 million, representing the ninth sequential revenue increase over the past 10 quarters. Management attributed the top-line growth to new client wins and high retention rates.

Negative Updates

Uncertainty Around Additional Genesis Recovery

Although HCSG recognized a $6.1 million recovery, any higher recovery remains subject to claim allowances, the ultimate amount of claims filed, and assets available for distribution. Management said the variables are not known, no timing can be specified, and it does not expect a scenario involving 100% recoveries.

Company Guidance

Guidance calls for Q4 revenue in the range of $535 million-$545 million, with NEXDINE expected to contribute over $150 million in annual revenue at comparable margins and be immediately accretive to earnings; 2027 revenue growth is being raised from the mid-single digits to low double digits, inclusive of a mid-single-digit growth target organically, while NEXDINE is viewed as a double-digit growth opportunity. Cost of services is expected to be managed in the 86% range, SG&A in the 9.5%-10.5% range with the longer-term goal of 8.5%-9.5%, and the 2026 effective tax rate is expected to be approximately 25%. For cash flow, Q4 is expected to have an $18 million negative impact from a six-day decrease in accrual days from 11 days in Q3 to five days in Q4; 2027 Q1 is expected to have a $19 million positive effect from a six-day increase to 11 days, Q2 about a -$9 million effect from a two-day decrease to nine days, Q3 about a $13 million positive effect from a two-day increase to 11 days, and Q4 of 2027 an $18 million or so negative effect from a five-day decrease to six days.

Healthcare Services Risk Analysis

Healthcare Services disclosed 23 risk factors in its most recent earnings report. Healthcare Services reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.Macroeconomic conditions, including geopolitical instability and related increases in fuel, energy and other input costs, may adversely affect our business and results of operations.Q2, 2026

Healthcare Services Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:HS1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASTH	64Neutral	$1.81B	44.14	5.09%	―	58.91%	58.36%
PNTG	60Neutral	$1.46B	44.32	9.51%	―	37.90%	15.84%
ARDT	56Neutral	$1.70B	21.87	5.21%	―	3.34%	-69.26%
USPH	52Neutral	$1.28B	504.88	-1.27%	2.13%	11.32%	-92.59%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACHC	43Neutral	$2.79B	-2.40	-50.02%	―	4.27%	-917.61%

* Healthcare Sector Average

Performance Comparison

DE:HS1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:HS1	Healthcare Services Group	21.60	6.30	41.18%
ACHC	Acadia Healthcare Company, Inc.	29.96	8.65	40.59%
USPH	U.s. Physical Therapy	85.83	1.09	1.28%
ASTH	Astrana Health Inc.	36.53	3.54	10.73%
PNTG	Pennant Group Inc	41.66	16.61	66.31%
ARDT	Ardent Health Partners, Inc.	12.03	-2.65	-18.05%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Healthcare Services AI Stock Analysis